Vericel (VCEL) Prepaid Assets (2010 - 2026)
Vericel (VCEL) posted Prepaid Assets of $8.2 million for Q2 2026, up 2.35% sequentially from $8.0 million in Q1 2026, and up 24.38% YoY from $6.6 million in Q2 2025.
Vericel (VCEL) Prepaid Assets (2010 - 2026) Analysis & Trends
Vericel has reported Prepaid Assets for 17 years, with the latest figure at $8.2 million in Q2 2026.
- Quarterly Prepaid Assets rose 24.38% year-over-year to $8.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.2 million (up 24.38% YoY) and the FY2025 annual result came in at $7.7 million, up 6.27% from the prior year.
- Prepaid Assets grew to $8.2 million in Q2 2026 per VCEL's latest filing, from $8.0 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $8.5 million in Q1 2025 and troughed at $4.4 million in Q3 2022.
- A 5-year average of $6.5 million and a median of $6.7 million in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets dropped 10.86% in 2023, then soared 71.26% in 2024.
- Over 5 years, Prepaid Assets stood at $4.8 million in 2022, then soared by 42.68% to $6.9 million in 2023, then gained by 6.33% to $7.3 million in 2024, then increased by 6.27% to $7.7 million in 2025, then advanced by 5.6% to $8.2 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $8.2 million, $8.0 million, and $7.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.18 Mn |
| Mar 31, 2026 | 7.99 Mn |
| Dec 31, 2025 | 7.74 Mn |
| Sep 30, 2025 | 8.01 Mn |
| Jun 30, 2025 | 6.58 Mn |
| Mar 31, 2025 | 8.52 Mn |
| Dec 31, 2024 | 7.29 Mn |
| Sep 30, 2024 | 7.88 Mn |
| Jun 30, 2024 | 6.43 Mn |
| Mar 31, 2024 | 7.78 Mn |
| Dec 31, 2023 | 6.85 Mn |
| Sep 30, 2023 | 5.43 Mn |
| Jun 30, 2023 | 5.04 Mn |
| Mar 31, 2023 | 4.54 Mn |
| Dec 31, 2022 | 4.80 Mn |
| Sep 30, 2022 | 4.41 Mn |
| Jun 30, 2022 | 4.81 Mn |
| Mar 31, 2022 | 5.09 Mn |
| Dec 31, 2021 | 4.25 Mn |
| Sep 30, 2021 | 4.69 Mn |